Global analysis of L1-transcriptomes identified IGFBP-2 as a target of ezrin and NF-κB signaling that promotes colon cancer progression

Oncogene

Volumn 32, Issue 27, 2013, Pages 3220-3230

  Ben Shmuel, A ^a   Shvab, A ^a   Gavert, N ^a   Brabletz, T ^b   Ben Ze'Ev, A ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

CRC; Ezrin; IGFBP 2; L1; NF B

Indexed keywords

EZRIN; SHORT HAIRPIN RNA; TRANSCRIPTOME;

ARTICLE; CANCER CELL; CARCINOGENESIS; CELL MOTILITY; CELL PROLIFERATION; COLON CANCER; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LIVER METASTASIS; MOLECULAR MECHANICS; MUTANT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; TRANSACTIVATION;

CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; COLONIC NEOPLASMS; CYTOSKELETAL PROTEINS; DISEASE PROGRESSION; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; NEOPLASM INVASIVENESS; NEURAL CELL ADHESION MOLECULE L1; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 84880264821     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.340     Document Type: Article

References (40)

1. Clevers H. Wnt/b-catenin signaling in development and disease. Cell 2006; 127: 469-480.
2. Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev 2007; 17: 45-51.
3. Brümmendorf T, Kenwrick S, Rathjen FG. Neural cell recognition molecule L1: from cell biology to human hereditary brain malformations. Curr Opin Neurobiol 1998; 8: 87-97.
4. Hortsch M. Structural and functional evolution of the L1 family: are four adhesion molecules better than one? Mol Cell Neurosci 2000; 15: 1-10.
5. Gavert N, Ben-Shmuel A, Raveh S, Ben-Ze'ev A. L1-CAM in cancerous tissues. Exp Opin Biol Ther 2008; 8: 1749-1757.
6. Conacci-Sorrell M, Ben-Yedidia T, Shtutman M, Feinstein E, Einat P, Ben-Ze'ev A. Nr-CAM is a target gene of the b-catenin/LEF-1 pathway in melanoma and colon cancer and its expression enhances motility and confers tumorigenesis. Genes Dev 2002; 16: 2058-2072.
7. Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P, Brabletz T et al. L1, a novel target of b-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol 2005; 168: 633-642.
8. Gavert N, Sheffer M, Raveh S, Spaderna S, Shtutman M, Brabletz T et al. Expression of L1-CAM and ADAM10 in human colon cancer cells induces metastasis. Cancer Res 2007; 67: 7703-7712.
9. Gavert N, Ben-Shmuel A, Lemmon V, Brabletz T, Ben-Ze'ev A. Nuclear factor-kB signaling and ezrin are essential for L1-mediated metastasis of colon cancer cells. J Cell Sci 2010; 15: 2135-2143.
10. Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 2002; 3: 586-599.
11. Fiévet B, Louvard D, Arpin M. ERM proteins in epithelial cell organization and functions. Biochim Biophys Acta 2007; 1773: 653-660.
12. Gavert N, Vivanti A, Hazin J, Brabletz T, Ben-Ze'ev A. L1-mediated colon cancer cell metastasis does not require changes in EMT and cancer stem cell markers. Mol Cancer Res 2011; 9: 14-24.
13. Gautreau A, Louvard D, Arpin M. Morphogenic effects of ezrin require a phosphorylation- induced transition from oligomers to monomers at the plasma membrane. J Cell Biol 2002; 10: 193-203.
14. Matsui T, Maeda M, Doi Y, Yonemura S, Amano M, Kaibuchi K et al. Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J Cell Biol 1998; 140: 647-657.
15. Ren L, Hong SH, Cassavaugh J, Osborne T, Chou AJ, Kim SY et al. The actincytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC. Oncogene 2009; 28: 792-802.
16. Mishra L, Bass B, Ooi BS, Sidawy A, Korman L. Role of insulin-like growth factor-I (IGF-I) receptor, IGF-I, and IGF binding protein-2 in human colorectal cancers. Growth Horm IGF Res 1998; 8: 473-479.
17. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915-928.
18. Bulut G, Hong SH, Chen K, Beauchamp EM, Rahim S, Kosturko GW et al. Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. Oncogene 2012; 19: 269-281.
19. Tang F, Wang D, Duan C, Huang D, Wu Y, Chen Y et al. Berberine inhibits metastasis of nasopharyngeal carcinoma 5-8F cells by targeting Rho kinase-mediated Ezrin phosphorylation at threonine 567. J Biol Chem 2009; 284: 27456-27466.
20. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23: 824-854.
21. Schütt BS, Langkamp M, Rauschnabel U, Ranke MB, Elmlinger MW. Integrinmediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol 2004; 32: 859-868.
22. Wang GK, Hu L, Fuller GN, Zhang W. An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin a5 is essential for IGFBP2-induced cell mobility. J Biol Chem 2006; 281: 14085-14091.
23. Mendes KN, Wang GK, Fuller GN, Zhang W. JNK mediates insulin-like growth factor binding protein 2/integrin a5-dependent glioma cell migration. Int J Oncol 2010; 37: 143-153.
24. Miyako K, Cobb LJ, Francis M, Huang A, Peng B, Pintar JE et al. PAPA-1 is a nuclear binding partner of IGFBP-2 and modulates its growth-promoting actions. Mol Endocrinol 2009; 23: 169-175.
25. Busund LT, Ow KT, Russell P, Crowe PJ, Yang JL. Expression of insulin-like growth factor mitogenic signals in adult soft-tissue sarcomas: significant correlation with malignant potential. Virchows Arch 2004; 444: 142-148.
26. Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR, Rosenfeld RG. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 1993; 76: 1031-1035.
27. Elmlinger MW, Deininger MH, Schuett BS, Meyermann R, Duffner F, Grote EH et al. In vivo expression of insulin-like growth factor-binding protein-2 in human gliomas increases with the tumor grade. Endocrinology 2001; 142: 1652-1658.
28. Hoeflich A, Reisinger R, Lahm H, Kiess W, Blum WF, Kolb HJ et al. Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter? Cancer Res 2001; 61: 8601-8610.
29. Karasik A, Menczer J, Pariente C, Kanety H. Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. J Clin Endocrinol Metab 1994; 78: 271-276.
30. El Atiq F, Garrouste F, Remacle BM, Sastre B, Pommier G. Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer. Int J Cancer 1994; 57: 491-497.
31. Kaaks R, Toniolo P, Akhmedkhanov A, Lukanova A, Biessy C, Dechaud H et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000; 92: 1592-1600.
32. Liou JM, Shun CT, Liang JT, Chiu HM, Chen MJ, Chen CC et al. Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer. J Clin Endocrinol Metab 2010; 95: 1717-1725.
33. Renehan AG, Painter JE, O'Halloran D, Atkin WS, Potten CS, O'Dwyer ST et al. Circulating insulin-like growth factor II and colorectal adenomas. J Clin Endocrinol Metab 2000; 85: 3402-3408.
34. Png KJ, Halberg N, Yoshida M, Tavazoie SF. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 2011; 481: 190-194.
35. Moore LM, Holmes KM, Smith SM, Wu Y, Tchougounova E, Uhrbom L et al. IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for highgrade gliomas. Proc Natl Acad Sci USA 2009; 106: 16675-16679.
36. Pollak M. The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Clin Cancer Res 2012; 18: 40-50.
37. So AI, Levitt RJ, Eigl B, Fazli L, Muramaki M, Leung S et al. Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res 2008; 14: 6944-6954.
38. Hlavin ML, Lemmon V. Molecular structure and functional testing of human L1CAM: an interspecies comparison. Genomics 1991; 11: 416-423.
39. Degenhardt T, Matilainen M, Herzig KH, Dunlop TW, Carlberg C. The insulin-like growth factor-binding protein 1 gene is a primary target of peroxisome proliferator- activated receptors. J Biol Chem 2006; 281: 39607-39619.
40. Langsrud Ø, Jørgensen K, Ragni Ofstad R, Næs T. Analyzing designed experiments with multiple responses. J Appl Stat 2007; 34: 1275-1296.